Exhibit 10.8


 


CERTAIN CONFIDENTIAL INFORMATION IN THIS
EXHIBIT WAS OMITTED BY MEANS OF MARKING SUCH

 INFORMATION WITH BRACKETS (“[***]”) BECAUSE THE IDENTIFIED CONFIDENTIAL INFORMATION
IS NOT

 MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.


 


Research Services Agreement


 


DETAILS


 


	PARTIES

	 
	Monash	Monash University (ABN 12 377 614 012), a body corporate constituted in accordance with the Monash University Act 2009 (Vic) of Wellington Road, Clayton, Victoria, Australia 3800
	Contracting
    Party	lncannex Healthcare Ltd (ABN 93 096 635 246) of Level 39, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000 (or its nominee)
	TERM
	 
	Commencement
    Date	(23/11/2020]
	Completion
    Date	(23/11/2023]
	RESEARCH
    SERVICES	 
	Research
    Services	The research services described in Annexure A
	Deliverables	Psi-GAD-1 Trial Brief Progress Report: 23/05/2021

 Psi-GAD-1 Trial Annual Progress Report: 23/11/2021

 Psi-GAD-1 Trial Brief Progress Report: 23/05/2022

 Psi-GAD-1 Trial Annual Progress Report: 23/11/2022

 Psi-GAD-1 Trial Brief Progress Report: 23/05/2023

 Psi-GAD-1 Trial Completion Report: 23/12/2023
	Milestones	Description	Due Date
	 	Determine basic trial design
    and register trial with ANZCTR	Before 23/03/2021
	 	Submission of trial protocol to HREC	Before 23/05/2021
	 	Commence patient recruitment	Before 23/09/2021 (subject to HREC delays)
	Key Personnel	Dr Paul Liknaitzky, Prof Murat Yucel, Prof Suresh Sundram 

School of Clinical Sciences
	Contracting Party Responsibilities	Not Applicable
	Background IP	Monash
Background IP: None Specified 

Contracting Party’s Background IP: None Specified 

Dr Liknaitzky’s Background IP: Outlined in Annexure B






 






    	Research Services Agreement Option 2 v6 (Apr 2020)
	 	Page 1 of 21 




     


    

 


	
    Are Monash approvals

    (eg ethics/biosafety) required? 
	
    YES –  Human Ethics

     
	☐ No
	PAYMENT	 	 
	Fees	
    Invoicing date or Milestone

    
	
    Amount $AUD (excl GST) 

	 	On the listed Commencement Date	$[***]
	 	15 months following the listed

                                                                                Commencement Date
	[***]
	 	TOTAL	[***]

	 	 	 
	
    Expenses

     
	Any shortfall arising from requested changes to the budget from the Contracting Party, and any additional activities outside the scope of the budgeted research trial requested by the Contracting Party and agreed to by the Principal Investigator team. Any such expenses are payable prior to above changes or activities occurring.
	 	 	 
	CONTACT
    DETAILS	 	 
	
    Address for notices
	
    Monash address:
	
    Contracting Party address:

	 	Attention:
	Vanalysa Ly Research

                                                                                                                                     Manager


	Attention:
	

	 	Address:
	[***]

	Address:
	[***]

	 	Phone:	[***]
	Phone:

	[***]

	 	Email:

	[***]
	Email:

	[***]

	Address
    for invoices	As above



 






    	Research Services Agreement Option 2 v6 (Apr 2020)
	 	Page 2 of 21 




     


    

 


	EXECUTED as an agreement	 	 
	 	 	 
	SIGNED for and on behalf of	 	 
	MONASH UNIVERSITY by	 	 
	its authorised officer:	 	 
	 	 	 
	/s/ Ross Coppel	 	 
	Ross Coppel	 	 
	Print Name	 	 
	 	 	 
	Senior Deputy Dean and Director of Research FMNHS	 	25-11-2020
	Title	 	Date
	 	 	 
	SIGNED by the CONTRACTING PARTY	 	 
	in accordance with section 127	 	 
	of the Corporations Act 2001 (Cth):	 	Signature of Director
	 	 	 
	/s/ Glenn Fowles	 	/s/ Troy Valentine
	GLENN FOWLES	 	TROY VALENTINE
	Name of Secretary Director 

XXXXX):

	 	Name of Director
	27 November 2020	 	27 November 2020
	Date	 	Date



 






    	Research Services Agreement Option 2 v6 (Apr 2020)
	 	Page 3 of 21 




     


    

 


Background


 


	A.	The Contracting Party wishes to engage Monash to perform the Research Services.



 


	B.	Monash agrees to perform the Research Services on the terms set out in this Agreement.



 


	C.	The parties acknowledge and agree that the Contracting Party may assign or novate
its rights and obligations under this Agreement to a nominee, being a subsidiary of the Contracting Party.



 


1.
Definitions


 


	1.	In this Agreement:



 


Agreement means this agreement,
the Details, and annexures (if any);


 


Australian
Sanctions Law means any law prohibiting or restricting dealings with proscribed states, persons or entities or seeking to prevent
the proliferation of weapons, including but not limited to laws implementing the sanctions imposed by the United Nations Security Council.;


 


Background
IP means Intellectual Property Rights owned or controlled by a Party at the Commencement Date or created or acquired independently
of this Agreement, that a Party makes available for the performance of the Research Services, and includes Improvements and any Background
IP specified in the Details;


 


Business Day means
a weekday on which banks are open in Melbourne, Australia.



 






    	Research Services Agreement Option 2 v6 (Apr 2020)
	 	Page 4 of 21 




     


    

 


Confidential
Information means information disclosed to a Party (Receiving Party) in any material
form by the other Party (Disclosing Party) in relation to the Research Services which is by
its nature confidential, which is designated by the Disclosing Party as confidential, or which the Receiving Party knows or ought to know
is confidential, but does not include (or, as the case requires, ceases to include) information which:


 


		(a)	is in the public domain at the time of disclosure;



 


		(b)	is published or otherwise becomes part of the public domain
through no fault of the Receiving Party;



 


		(c)	was in the possession of the Receiving Party at the time of
disclosure without an obligation of non-disclosure to the Disclosing Party;



 


		(d)	is received from a third party without an obligation of non-disclosure;



 


		(e)	is independently created by or on behalf of the Receiving
Party by persons who had no knowledge of the Confidential Information; or



 


		(f)	is required to be disclosed by law.



 


Controller means, in relation to a person:


 


		(a)	a receiver, receiver and manager, administrator or liquidator
(whether provisional or otherwise) of that person or that person’s property; or



 


		(b)	anyone else who (whether or not as agent for the person) is
in possession, or has control, of that person’s property to enforce an encumbrance;



 


Details
mean the matters set out in the table on the front page(s) of this Agreement headed “Details”;


 


Developed
IP means Intellectual Property Rights created or developed by or on behalf of Monash in the course of performing the Research
Services, including the Deliverables, but expressly excluding Background IP;


 


Force Majeure Event has the meaning given to that
term in clause 10.1;


 


GST means
a goods and services tax imposed on the supply of goods and services (including intellectual property) under the A New Tax System (Goods
and Services Tax) Act 1999 (Cth);


 


Improvements
means any improvements, enhancements, modifications, adaptations, extensions, developments, mutations, application of Background IP, and
all other technical advances made by or on behalf of Monash to Background IP, whether or not protected by statute, in the course of providing
the Research Services;


 






    	Research Services Agreement Option 2 v6 (Apr 2020)
	 	Page 5 of 21 




     


    

 


Insolvency
Event means, in respect of a Party, any one or more of the following events or circumstances:


 


		(a)	a winding up, dissolution, liquidation, provisional liquidation,
administration or bankruptcy;



 


		(b)	having a Controller or analogous person appointed to it or
any of its property;



 


		(c)	being unable to pay any of its debts as and when due and payable
or being deemed to be insolvent under any provision of the Corporations Act 2001 (Cth) or any other law;



 


		(d)	seeking protection from its creditors under any law, entering
into a compromise, moratorium, assignment, composition or arrangement with, or for the benefit of, any of its members or creditors, or



 


		(e)	any analogous event or circumstance to those described in
paragraphs (a) to (d) under any law,



 


unless such event or circumstance
occurs as part of a solvent reconstruction, amalgamation, compromise, arrangement, merger or consolidation approved by the other party
(which approval is not to be unreasonably withheld or delayed);


 


Intellectual
Property Rights means all rights resulting from intellectual activity whether capable of protection by statute, common law
or in equity, including copyright, discoveries, inventions, patent rights, registered and unregistered trade marks, design rights, circuit
layouts, plant varieties, the right to have confidential information kept confidential and all rights and interests of a like nature,
together with any and all documentation relating to such rights and interests;


 


Party
means Monash or the Contracting Party and Parties means both of them;


 


Personal
Information means ‘personal information’ as defined in the Privacy and Data Protection Act 2014 (Vic) and ‘health information’
as defined in the Health Records Act 2001 (Vic);


 


Research
Services means the research services to be provided by Monash under this Agreement, as described in the Details;


 


Term
means the term of this Agreement as set out in clause 2.


 


	2.	All other capitalised expressions in this Agreement have the meanings given to them in the Details.



 


	2.	Term



 


This Agreement
will commence on the Commencement Date and will continue until the Completion Date, unless terminated earlier in accordance with this
Agreement.


 






    	Research Services Agreement Option 2 v6 (Apr 2020)
	 	Page 6 of 21 




     


    

 


		3.	Research Services



 


		3.1.	Performance



 


		(a)	Monash agrees to:



 


		(i}	carry out and complete the Research Services during the Term
in accordance with the terms of this Agreement, including providing the Deliverables and complying with the Milestones as set out in
the Details;



 


		(ii}	carry out the Research Services in accordance with all reasonable
professional, scientific and ethical principles and standards;



 


		(iii)	use reasonable endeavours to obtain any required Monash approvals and is not required
to commence the Research Services until such approvals are obtained. If Monash approvals are unable to be obtained or obtained in a timely
manner, the Parties will communicate with each other and decide whether to terminate this Agreement. If the Parties agree to terminate
this Agreement under this clause, Monash will be entitled to payment for work done and Expenses incurred up to the date of termination;
and



 


		(iv)	use reasonable endeavours to ensure that any Key Personnel are actively involved
in delivering the Research Services. Where the Key Personnel leave the employ of Monash or are unable to perform the Research Services,
Monash will use reasonable endeavours to provide a replacement subject to the Contracting Party’s approval which will not be unreasonably
withheld or delayed. If a suitable replacement cannot be found or is not agreed to by the Parties, the Parties will communicate with each
other and decide whether to terminate this Agreement. If the Parties agree to terminate this Agreement under this clause, Monash will
be entitled to payment for work done and Expenses incurred up to the date of termination, and reasonable costs necessarily incurred arising
from such termination.



 


		(b}	The Contracting Party acknowledges and agrees that to the
extent that Monash is unable to perform the Research Services, or there is a change in the scope of the Research Services, due to any
act or omission of the Contracting Party or any Force Majeure Event, Monash may, acting reasonably, propose amendments to the Details
and the Fees. Monash will promptly provide the Contracting Party with notice of such proposed amendments, whereupon the Parties will
meet and agree on changes (if any}. If the Parties are unable to agree on the changes, then the Agreement will be terminated on a date
agreed between the Parties (both acting reasonably} and Monash will be paid all Fees and Expenses up to the date of termination, including
any committed Fees and Expenses.



 


	3.2.	Contracting Party Responsibilities



 


		(a}	The Contracting Party will comply with or perform the Contracting
Party Responsibilities at its sole expense and will promptly provide Monash with any materials listed under the Contracting Party Responsibilities
(Materials}, in addition to all information and assistance reasonably required to enable
Monash to carry out the Research Services.



 


		(b}	The Contracting Party will:



 


		(i}	ensure that the Materials are accurate, complete and current;



 


		(ii}	ensure that it is entitled to supply the Materials to Monash
for the purpose of the Research Services;



 






    	Research Services Agreement Option 2 v6 (Apr 2020)
	 	Page 7 of 21 




     


    

 


		(iii)	ensure that the use of the Materials in connection with the Research Services is
lawful and all required consents, permissions or authorisations relating to such use have been obtained;



 


		(iv)	be responsible for arranging for the packaging and delivery of all Materials to Monash
and for all associated costs. Monash will not be responsible for any damage to the Materials prior to delivery to it;



 


		(v)	unless specified by written notice to Monash, ensure that the Contracting Party
Materials, when used by Monash for the Research Services, are not reasonably capable of constituting a threat to safety, health, life,
property or the environment; and



 


		(vi)	ensure that it provides Monash all relevant information regarding the Materials,
including, without limitation, information relating to the safe, secure and appropriate transportation, use, storage and disposal of the
Materials.



 


	4.	Payment



 


	4.1.	Fees and Expenses



 


In consideration
of Monash performing the Research Services, the Contracting Party must pay to Monash the Fees and Expenses in the manner specified in
the Details.


 


	4.2.	Late Payment



 


Monash
may suspend performance of the Research Services or its other obligations under this Agreement until any overdue amounts are paid. The
Contracting Party will pay, if demanded, interest at a rate 2% higher than the rate fixed from time to time under the Penalty
Interest Rates Act 1983 (Vic) on any amounts which the Contracting Party has not paid to Monash by the due date. Interest is
to be calculated daily from the due date and will continue until the overdue amounts are paid.


 


	5.	GST



 


	5.1.	Monash
                                            shall submit invoices for amounts payable according to the Details and the Contracting Party
                                            agrees and undertakes to pay such amounts within thirty {30) days of receipt of a
                                            valid tax invoice.



 


	5.2.	Any amount payable by the Contracting Party for anything supplied under this Agreement
is expressed exclusive of GST. The Contracting Party will, on issue of a valid tax invoice (or other documentation required under GST
laws to enable tax in-put credits to be claimed), pay Monash an additional amount equal to the GST liability payable by Monash on the
supply within 30 days of the invoice.



 


	6.	Intellectual Property Rights



 


	6.1.	Background IP



 


		(a)	Each Party agrees that it will not have any claim, ownership or interest in the other Party’s Background
IP, except as specified in this Agreement.



 






    	Research Services Agreement Option 2 v6 (Apr 2020)
	 	Page 8 of 21 




     


    

 





		(b)	Where Background IP is contributed by the Contracting Party, the Contracting Party
grants Monash a non-exclusive, royalty-free licence for the Term to use, reproduce, communicate, modify and adapt that Background IP solely
for the purpose of providing the Research Services.



 


		(c)	To the extent that Improvements have been made by Monash to the Contracting Party’s
Background IP (Contracting Party Improvements), Monash agrees that title to, and all Intellectual Property Rights (including future
copyright) in the Contracting Party Improvements will automatically be transferred and assigned to the Contracting Party, encumbrance
free, such transfer and assignment to be effective on payment in full of the Fees and Expenses.



 


		(d)	Monash agrees to execute all such further documents and do all such further acts,
at the Contracting Party’s expense, that are necessary to effect the assignment in clause 6.l(c).



 


	6.2.	Ownership of Developed IP



 


		(a)	Title to, and all Intellectual Property Rights (including future copyright) in,
the Developed IP will automatically be transferred and assigned to the Contracting Party, encumbrance free, such transfer and assignment
to be effective on payment in full of the Fees and Expenses.



 


		(b)	Monash agrees to execute all such further documents and do all such further acts,
at the Contracting Party’s expense, that are necessary to effect the assignment of the Developed IP to Contracting Party under clause
6.2(a).



 


		(c)	Where the use of any Monash Background IP is necessary for the
                                                                                                                                      Contracting Party to be able to fully utilise the Developed IP, Monash will grant the Contracting Party a non-exclusive, royalty
                                                                                                                                      free licence, to use, reproduce, communicate, publish, adapt and exploit that Background IP in conjunction with the Developed IP to
                                                                                                                                      the extent necessary and solely for the purpose of utilising the Developed IP.



 


	6.3.	Licence to Monash



 


		(a)	The Contracting Party grants to Monash a non-exclusive, irrevocable, perpetual,
free, worldwide licence to use, reproduce, communicate, publish, adapt and exploit the Developed IP solely for research, teaching and
publication purposes (subject to Monash’s compliance with clause 9.2).



 


		(b)	Where the use of any Background IP of the Contracting Party is necessary for Monash
to be able to fully utilise the Developed IP in accordance with the licence granted to it under clause 6.3(a), the Contracting Party grants
Monash a non-exclusive, irrevocable, perpetual, free, worldwide licence to use, reproduce, communicate, publish, adapt and exploit that
Background IP in conjunction with the Developed IP solely for the purpose of utilising the Developed IP in accordance with clause 6.3(a).



 






    	Research Services Agreement Option 2 v6 (Apr 2020)
	 	Page 9 of 21 




     


    

 





	7.	Liability, warranties and indemnity



 


	7.1.	Acknowledgement



 


The Contracting Party acknowledges and agrees that:



 


		(a)	while Monash will exercise reasonable care and diligence and comply with its obligations
under this Agreement in carrying out the Research Services, research work is by its nature uncertain and that the outcomes of the Research
Services and its ability to produce commercially useful results cannot be assured;



 


		(b)	Monash makes no representation and gives no warranties that any Developed IP will
be patentable;



 


		(c)	Monash is not required to make enquiries or undertake patent searches to ascertain
whether any Developed IP or Background IP infringes any third party Intellectual Property Rights;



 


		(d)	the Developed IP is a result of experimental research and as such, the Contracting
Party must use its own judgement as to the applicability and appropriateness of the Developed IP for the Contracting Party’s intended
use;



 


		(e)	the Contracting Party assumes sole responsibility and risk in interpreting, using,
exploiting and protecting the Developed IP (including any findings, results and recommendations contained within); and



 


		(f)	given the above, to the maximum extent permitted by law, subject to clause 7.7
and notwithstanding anything else in this Agreement, Monash will not be liable to the Contracting Party for any loss or damage arising
from:



 


		(i)	Contracting Party’s (or any of its users) use of any Developed IP (including any
findings, results and recommendations contained within); or



 


		(ii)	Monash’s failure to perform work on time or within estimated costs, provided that
Monash has exercised reasonable care and diligence and complied with its other obligations under this Agreement in carrying out the Research
Services.



 


	7.2.	Developed IP and Background IP limitation on warranty



 


Monash makes
no representations and gives no warranties that the Developed IP, Monash Background IP, or any Improvements to the Contracting Party’s
Background IP when used by the Contracting Party in accordance with the terms of this Agreement or otherwise, will not infringe upon any
third party Intellectual Property Rights.


 


	7.3.	Limitation of condition, guarantee or warranty



 


Monash will
exercise all reasonable care and diligence and comply with its other obligations under this Agreement in carrying out the Research Services
but where permitted by law (including, without limitation, under the Competition and Consumer Act 2010) specifically excludes any condition,
guarantee or warranty either express or implied, as to the standard or timeliness of work, the accuracy of, or fitness for a particular
purpose of, the Research Services.


 






    	Research Services Agreement Option 2 v6 (Apr 2020)
	 	Page 10 of 21 




     


    

 





	7.4.	Limitation of liability



 


		(a)	To the fullest extent permitted by law (including, without limitation, the Competition
and Consumer Act 2010), Monash’s liability under any condition, guarantee or warranty which cannot legally be excluded is limited, at
the option of Monash, to supplying the Research Services again or paying
the cost of having the Research Services supplied again.



 


		(b)	Monash’s liability under this Agreement is reduced to the extent that any damage,
liability, loss or cost arises from or is attributable to any act or omission of the Contracting Party, its officers, employees, agents
or contractors.



 


	7.5.	Contracting Party to bear responsibility and risk



 


The Contracting
Party assumes sole responsibility and risk in interpreting, using and exploiting the Developed IP and any Improvements to its Background
IP (including any findings, results and recommendations therein) and shall indemnify Monash and its officers, employees and agents against
any actions, proceedings, suits, claims and demands arising from such interpretation, use or exploitation by the Contracting Party, its
officers, employees, contractors, agents, successors, licensees or assigns; save to the extent such loss, damage or expense is directly
attributable to any breach of this Agreement by Monash or any negligent, fraudulent, or unlawful act or omission by Monash, its officers,
employees or agents.


 


	7.6.	Special, indirect or consequential loss or damage



 


To the
fullest extent permitted by law, Monash will not be liable to the Contracting Party or any third party for any special, indirect or consequential
loss or damage, or loss of anticipated profits, revenue, data or opportunity, arising from or in any way relating to this Agreement, whether
in tort (including negligence), contract, statute, equity or otherwise.


 


	7.7	Maximum liability



 


Notwithstanding
any other clause in this Agreement and to the fullest extent permitted by law, Monash’s liability arising from its obligations under this
Agreement or in any other manner related to this Agreement, whether in tort (including negligence), contract, statute, equity or otherwise,
will not in the aggregate exceed the Fees and Expenses paid under this Agreement.


 


	8.	Privacy



 


	8.1.	Each Party must handle any Personal Information relating to the Research Services
or under this Agreement in accordance with the Privacy and Data Protection Act 2014 (Vic) and the Health Records Act 2001 (Vic),
including the Information Privacy Principles and Health Privacy Principles, and any code of practice or guidelines made under these Acts,
and must co-operate with all efforts by either Party to comply with these laws, codes and guidelines, including in response to a complaint
or a suspected privacy breach.



 


	8.2.	Where the Contracting Party discloses any Personal Information it receives from
Monash, or it receives, creates or holds in connection with this Agreement, to any third party for the purposes of this Agreement, the
Contracting Party must ensure that the third party is subject to enforceable obligations requiring the third party to comply with the
obligations in this clause as if the third party were the Contracting Party, and to enforce these obligations against the third party
if required to do so by Monash.



 






    	Research Services Agreement Option 2 v6 (Apr 2020)
	 	Page 11 of 21 




     


    

 





	8.3.	To the extent that:


 


		(a}	the European Union’s General Data Protection Regulation (2016/679}
(GDPR} is applicable to Monash or the Contracting Party (or both} in the context of this Agreement; and



 


		(b}	GDPR provisions impose obligations on Monash or the Contracting
Party (or both} which are additional to the obligations in clauses 8.1 or 8.2 in respect of personal data as that term is defined in
the GDPR,



 


the Contracting Party shall comply
with those GDPR provisions in addition to its obligations under clauses 8.1 and 8.2.


 


	8.4.	The Contracting Party will indemnify and will continue to indemnify, defend and
hold harmless Monash, its officers and employees from and against all claims, losses, liabilities, damages, settlements, expenses and
costs (including reasonable legal costs} arising out of or relating to the Contracting Party’s breach of this clause 8 or a breach by
any third party of the obligations it undertakes under clause 8.2.



 


	9.	Confidentiality
                                            and Publication



 


	9.1.	Obligations of confidentiality



 


Each party
(Receiving Party} receiving, possessing or otherwise acquiring Confidential Information of
the other party (Disclosing Party} acknowledges that the Disclosing Party’s Confidential Information
is the property of and confidential to or a trade secret of the Disclosing Party. The Receiving Party must:


 


		(a}	keep the Disclosing Party’s Confidential Information confidential
and not directly or indirectly disclose, divulge or communicate that Confidential Information to, or otherwise place that Confidential
Information at the disposal of, any other person without the prior written approval of the Disclosing Party;



 


		(b}	take all reasonable steps to secure and keep secure all Disclosing
Party’s Confidential Information in its possession or control; and



 


		(a)	not deliberately memorise, use, modify, reverse engineer or
make copies, notes or records of the Disclosing Party’s Confidential Information for any purpose other than in connection with the performance
by the Receiving Party of its obligations under this Agreement.



 


	9.2.	Publication rights



 


		(a}	With the exception of Specified Confidential Information outlined
in 9.2(b}, Monash may publish the Developed IP after providing the Contracting Party with a thirty (30} day period in which to review
each proposed publication to identify any inadvertent disclosure of the Contracting Party’s Specified Confidential Information.



 






    	Research Services Agreement Option 2 v6 (Apr 2020)
	 	Page 12 of 21 




     


    

 





		(b}	Specified Confidential Information cannot be published or
otherwise communicated without prior written approval from the Contracting Party. When and if the Contracting Party deems further items
should be added to this list of items comprising Specified Confidential Information, a Contract Addendum will be provided to Monash by
the Contracting Party, outlining the proposed items for agreement. Monash’s agreement with the addition of these items as Specified Confidential
Information will not be unreasonably withheld or delayed.
At the date of this Agreement, Specified Confidential Information consists of:


 


		(i}	Psi-GAD Trial Treatment Manual



 


		(ii}	Psi-GAD Trial Therapist Training Manual



 


		(c)	If the Contracting Party notifies Monash in writing within
the thirty (30} day period that the proposed publication should not be published due to clause 9.2(a), then the Parties agree that they
will communicate with each other in good faith with a view to reaching agreement on whether the proposed publication can be published
in some amended form. If the Contracting Party does not respond to Monash within the thirty (30} day period, approval to publish is deemed
to be given. Such approvals are not to be unreasonably withheld or delayed.



 


		(d}	Excluding the Specified Confidential Information and any information
the subject of a Contract Addendum, Monash researchers may discuss the project without written approval from the Contracting Party, for
media and other forums such as academic talks, interviews for radio, television, film, other media, or other forums as appropriate to
promote the research.



 


	9.3.	The Contracting Party shall not publish, or make a public statement about, any
findings, results, outcomes or recommendations arising from the Research Services in association with the name, trade marks or logos of
Monash or the name of Monash staff, without the express written approval of Monash (which approval is not to be unreasonably withheld
or delayed}.



 


	9.4.	The Contracting Party shall not represent that Monash or any Monash staff in any
way endorse, support or approve of, any products, services, intellectual property or business of the Contracting Party, unless Monash
has given its express written consent to such representation.



 


	10.	Force Majeure



 


	10.1.	Neither party will be liable for any delay or failure to perform its obligations
under this Agreement where such delay or failure is due to any event beyond that party’s reasonable control including by reason of any
of the following: labor disturbances, shortages or disputes of any kind; natural disasters; national emergencies; government directives
or restrictions; civil disorders; acts of war or aggression; acts of God; failure of utilities; mechanical breakdowns; material shortages;
epidemics; pandemics (including but not limited to COVID-19}; or similar occurrences (Force Majeure Event}. This clause does not
apply to the Contracting Party’s obligation to pay the Fees and Expenses, provided that Monash is ready, willing and able to perform its
obligations under this Agreement.



 


	10.2.	The Party unable to perform its obligations as a result of a Force Majeure Event must:



 


		(a}	notify the other Party promptly of any delay or failure to
perform referred to in clause 10.1; and



 


		(b}	use reasonable endeavours to resume performance in accordance
with this Agreement as soon as practically possible.






 






    	Research Services Agreement Option 2 v6 (Apr 2020)
	 	Page 13 of 21 




     


    

 


	11.	Dispute Resolution



 


	11.1.	If any dispute arises between the Parties out of or in connection with this Agreement,
the Parties shall endeavour to resolve that dispute by negotiation in good faith.



 


	11.2.	If the dispute is not mutually resolved within 20 Business Days of a Party serving
on the other Party a written dispute notice, each Party must nominate one senior representative who shall meet as soon as practicable
for the purpose of endeavouring to resolve the dispute.



 


	11.3.	If within 20 Business Days after submitting the dispute to senior representatives
the Parties fail to resolve the dispute then the Parties shall have the right to seek the determination of the dispute in a court or tribunal
exercising jurisdiction over such matters in Victoria, Australia.



 


	11.4.	The provisions of this clause 11 shall not preclude a Party from seeking urgent
interlocutory relief in a court of competent jurisdiction.



 


	12.	Termination



 


	12.1.	Either Party (Terminating Party) may terminate this Agreement immediately
by notice in writing to the other Party (Defaulting Party) if:



 


		(a)	the Defaulting Party is in breach of this Agreement and the Defaulting Party fails
to remedy the breach, where it is capable of remedy, within 20 Business Days of receiving written notice of the breach from the Terminating
Party;



 


		(b)	the Defaulting Party is in breach of this Agreement and the breach is not capable
of remedy;



 


		(c)	an Insolvency Event occurs in relation to the Defaulting Party; or



 


		(d)	the Parties agree that the Milestones will not be met, whether because it appears
the outcomes will not be attained or for technical reasons the work should not continue.



 


	12.2.	Monash may terminate this Agreement immediately by notice in writing if the Contracting
Party breaches clause 13.11.



 


	12.3.	Upon termination of this Agreement for any reason:



 


		(a)	each Party must immediately cease using the other Party’s Confidential Information
and promptly return to the other Party its Confidential Information or, if requested by the other Party, destroy it;



 


		(b)	in the case of termination pursuant to clause 12.l(d), the Contracting Party will
meet payments due to Monash up to the effective date of termination, plus the reasonable costs and committed expenses of Monash which
cannot be avoided notwithstanding the termination; and



 


		(c)	the termination will be without prejudice to any other remedies available to any Party.



 






    	Research Services Agreement Option 2 v6 (Apr 2020)
	 	Page 14 of 21 




     


    

 





	13.	General



 


	13.1.	Nature of obligations



 


		(a)	Any provision in this Agreement which binds more than one person binds all of
those persons jointly and each of them severally.



 


		(b)	Each obligation imposed on a Party by this Agreement in favour of another is a
separate obligation.



 


	13.2.	Entire understanding



 


This Agreement contains the
entire understanding between the Parties concerning the subject matter of this Agreement and supersedes, terminates, and replaces all
prior agreements between the Parties.


 


	13.3.	Further assurances



 


A Party,
at its own expense and within a reasonable time of being requested by the other Party to do so, must do all things and execute all documents
that are reasonably necessary to give full effect to this Agreement.


 


	13.4.	No waiver



 


		(a)	A failure, delay, relaxation or indulgence by a Party in exercising any power
or right conferred on the Party by this Agreement does not operate as a waiver of the power or right.



 


		(b)	A single or partial exercise of the power or right does not preclude a further
exercise of it or the exercise of any other power or right under this Agreement.



 


		(c)	A waiver of a breach does not operate as a waiver of any other breach.



 


	13.5.	Severability



 


Any provision of this Agreement
which is invalid in any jurisdiction must, in relation to that jurisdiction:


 


		(a)	be read down to the minimum extent necessary to achieve its validity, if applicable;
and



 


		(b)	be severed from this Agreement in any other case,



 


without
invalidating or affecting the remaining provisions of this Agreement or the validity of that provision in any other jurisdiction.


 


	13.6.	No assignment



 


		(a)	Subject to clause 13.6, a Party cannot assign or otherwise transfer the benefit
of this Agreement without the prior written consent of the other party.



 


		(b)	Monash agrees that the Contracting Party may assign or novate its rights and obligations
under this Agreement to a subsidiary of the Contracting Party.



 






    	Research Services Agreement Option 2 v6 (Apr 2020)
	 	Page 15 of 21 




     


    

 





	13.7.	Consents and approvals



 


Where anything
depends on the consent or approval of a party then, unless this Agreement provides otherwise, that consent or approval may be given conditionally
or unconditionally or withheld, in the absolute discretion of that party.


 


	13.8.	No variation



 


This Agreement cannot be amended or varied
except in writing signed by the Parties.


 


	13.9.	Governing law and jurisdiction



 


		(a)	This Agreement is governed by and must be construed in accordance with the laws
in force in the State of Victoria, Australia.



 


		(b)	The Parties submit to the exclusive jurisdiction of the courts of that State and
the Commonwealth of Australia in respect of all matters arising out of or relating to this Agreement, its performance or subject matter.



 


	13.10.	Notices



 


All notices to be served under this
Agreement:


 


		(a)	may be served personally, via email, or sent by express post to the address of
the recipient as set out in the Details (or to such alternative address which has been notified by the recipient to the sender); and



 


		(b)	will be deemed to have been given:



 


		(i)	if served personally, on the date upon which it is served;



 


		(ii)	if sent by email, upon receipt by the sender of confirmation that the notice has been sent in its entirety
to the recipient; and



 


		(iii)	if sent by express post, two Business Days after the date of posting.



 


	13.11.	Sanctions



 


		(a)	Where the Contracting Party is an Australian entity or person:



 


The Parties
acknowledges their obligations under Australian sanctions laws, including but not limited to those arising under the Charter of the
United Nations Act 1945 (Cth) and the Autonomous Sanctions Act 2011 (Cth), and undertake to comply with those obligations.


 






    	Research Services Agreement Option 2 v6 (Apr 2020)
	 	Page 16 of 21 




     


    

 





		(b)	Where the Contracting Party is not an Australian entity or person:



 


The Contracting Party undertakes
not to engage in any act which may result in Monash contravening an Australian Sanctions Law.


 


	13.12.	Electronic Signing & Counterparts



 


		(a)	Each Party agrees that this Agreement may be executed by electronic signature (regardless
of the form of electronic signature utilised) and that this method of signature is conclusive of the parties’ intention to be bound by
this Agreement as if physical signing had occurred.



 


		(b)	This Agreement may be executed in any number of counterparts and by the parties
on separate counterparts. Each counterpart constitutes the agreement of each party who has executed and delivered that counterpart. Each
party may communicate its execution of this Agreement by successfully transmitting an executed copy of the Agreement by an electronic
method to each party.



 


	13.13.	Relationship of parties



 


The Parties
are independent contracting parties and nothing in this Agreement may be construed as creating a relationship of partnership, joint venture,
employer and employee, principal and agent, or trustee and beneficiary, nor does it grant either Party any authority to assume or to create
any obligation on behalf of, or in the name of, the other Party.


 


	13.14.	Survival of obligations



 


Clauses 4, 5.2, 6, 7, 8, 9, 11, 12.3
and 13 survive expiry or termination of this Agreement.


 






    	Research Services Agreement Option 2 v6 (Apr 2020)
	 	Page 17 of 21 




     


    

 





Annexure A - Trial
Summary


 


A Phase 2A randomised double-blind active-placebo-controlled
trial to assess the safety and efficacy of psilocybin-assisted psychotherapy for Generalized Anxiety Disorder [Psi-GAD-1]


 





	Study Type	 	Double blind active-placebo controlled Phase 2A RCT
	 	 	 
	
    Estimated

enrolment:
	 	
    72
participants

	 	 	 
	Primary Indication:	 	
    Generalised
Anxiety Disorder (GAD) 

	 	 	 
	Treatment:	 	Psilocybin-assisted psychotherapy
	 	 	 
	Treatment sessions:	 	Two psilocybin or active-placebo dosing sessions; 9 non-drug psychotherapy sessions. [Open-label extension arm for placebo group after 26 week follow-up and unblinding: single psilocybin dosing sessions; 3 additional non-drug psychotherapy sessions].
	 	 	 
	Primary outcomes:	 	Safety, efficacy
	 	 	 
	
    Secondary

outcomes: 
	 	Quality of life, functional impairment, comorbidities, mechanisms
	 	 	 
	Funding (source)	 	
    [***] 

	 	 	 
	
    Timing

    
	 	[***]




 






    	Research Services Agreement Option 2 v6 (Apr 2020)
	 	Page 18 of 21 




     


    

 


Investigators


 


Chief Principal Investigator and Trial Co-ordinator:
Paul Liknaitzky 

Principal Investigators: Murat Yucel, Suresh Sundram


 


Brief Description


 


Phase 3 trials pursuing FDA and EMA drug licencing
for psilocybin-assisted psychotherapy to treat depression are on course to commence in the US and Europe in 2021. This trial will be a
double blind active-placebo controlled RCT assessing safety, efficacy, feasibility and therapeutic mechanisms of psilocybin-assisted psychotherapy
for Generalised Anxiety Disorder (GAD). With support from the Usona Institute, and based on the treatment protocols of leading psychedelic
research groups, this FDA-compliant pivotal trial is likely to be a world-first using psilocybin to treat GAD. Ancillary options and sub-studies,
subject to additional funding or partnerships, include: biomarkers, neuroimaging, Lifestyle Medicine continued care program, performance-based
tasks, and app-based ecological momentary assessment. In addition, the trial will fund the development of a specialist training program
for trial therapists using psilocybin in the treatment of GAD.


 








Dosing and Psychotherapeutic support


[***]
[***]Primary objectives include:


 


[***]


 





Secondary objectives include:

 


[***]


 











    	Research Services Agreement Option 2 v6 (Apr 2020)
	 	Page 19 of 21 




     


    

 


	Indicative Budget Summary: Psi-GAD-1 trial [30-36 months duration]	 	Total {excl GST)
	Study IP and preparation	 	[***]
	Pharmacy	 	[***]
	Project management, patient assessments, research staff	 	[***]
	Administration, set-up, training	 	[***]
	Clinical treatment/ Laboratory assessment	 	[***]
	Miscellaneous (incl participant reimbursement)	 	[***]
	Total	 	[***]




 






    	Research Services Agreement Option 2 v6 (Apr 2020)
	 	Page 20 of 21 




     


    

 


Annexure B: Background IP


 


Dr Liknaitzky has developed Background IP in a private
capacity, and provides the Contracting Party with a non-exclusive, royalty-free licence in perpetuity to use, reproduce, communicate,
modify and adapt that Background IP. Dr Liknaitzky retains the rights to use this background IP in future research, development, and other
projects. This Background IP consists of a Research Trial Protocol Prototype and a Therapist Training Program Prototype, detailed below.


 


Research
Trial Protocol Prototype [psilocybin-assisted psychotherapy clinical trial protocol]: consists of an extensive document (~so
pages) that includes the following sections:


 


	●	Psychedelic Compounds In Medicine, Psilocybin Summary, Safety Of Psilocybin Use, Risks Of Psilocybin
Use.



	●	Study Design, Type Of Study, Sample Size, Source Population, Expected Duration Of Participation, Study
Measures, lnvestigational Product (Dosage, Storage, Handling And Labelling), Psychotherapy, Concomitant Medications And Psychotropics,
Rescue Medications.



	●	Participant Recruitment, Consenting Process, Screening For Eligibility, Clinical Laboratory Assessments,
Inclusion Criteria, Exclusion Criteria, General Medical Exclusion Criteria, Psychiatric Exclusion Criteria,



	●	Study Procedures, Data Points And Associated Procedures, Premature Discontinuation Of The Study, Removal
Or Withdrawal Of Participants From The Study.



	●	Potential Benefits, Possible Risks And Discomforts Associated With Assessment Measures, Possible Risks
And Discomforts Associated With Non-Drug And Experimental Psychotherapy, Possible Risks Of Receiving Psilocybin, Cardiovascular And Sympathomimetic
Effects, Possible Psychological Distress Associated With Receiving Psilocybin, Reproductive And Developmental Risks, Drug Dependence And
Abuse Potential, Risk Mitigation, Adverse Events, Serious Adverse Events, Medical Emergencies, Serious Adverse Event Collection.



 


Therapist
Training Program Prototype [psilocybin-assisted psychotherapy therapist training program]: consists of a document (~25 pages)
outlining training schedule, national and international trainers, educational material list, and training content summaries for each
session (outline of in- person schedule shown below):


 


	●	FOUNDATIONS: Setting the scene on this training; Introductions, broader context of PP; Historic and
research overview of PP; Group discussion: questions, concerns; Key trial details; Set-setting protocol.



	●	PREPARATION: AIMS: Key Aims Of Preparation; PRACT: Practical Approaches To Preparation; GUEST: Intro,
Therapist Qualities, Past Challenges For Psychedelic Research Groups; GUEST: Principles Of PP, Stories From The Field; Clinical Exercise:
Somatic And Mindfulness Tools Within Preparation; ROLE PLAY: Preparation; DISCUSSION: Preparation.



	●	DOSING: AIMS: Psychedelic experience and supporting therapeutic mechanisms; PRACT 1: Dosing skills;
PRACT 2: Risks, safety monitoring, symptoms, adverse events, rescue, reporting, referral; CLINICAL EXERCISE: Dosing skills; ROLE PLAY:
dosing; DISCUSSION: dosing.



	●	INTEGRATION: AIMS: Key aims of Integration; PRACTICAL: integration; ROLE PLAY: Integration; DISCUSSION:
Integration.



	●	SYNTHESIS: Trial requirements and key pragmatics for therapists, plus Q&A; GUEST: Safety response,
red flags, pre-emptive support, therapist anxiety; PRACTICAL: General considerations, incl screening, rapport, expectation/intention,
red flags, dyadic challenges; PRACTICAL: Specific tips, statements, and exercises for each phase; DISCUSSION: take outs, final questions;
GUEST: Case studies from TRD trial, tips and hard- earned wisdom, Q&A.



 






    	Research Services Agreement Option 2 v6 (Apr 2020)
	 	Page 21 of 21